Nutra Pharma Corp. (NPHC) Stock Price & Analysis
Nutra Pharma Corp. (NPHC) — price $0.0002 (0.00%), as of the Nov 18, 2026 trading session; market cap $1.43M.
Educational signal · not a buy or sell recommendation · How to read this
Nutra Pharma Corp. · NPHC
Nutra Pharma Corp. is a biopharmaceutical company focused on acquiring, licensing, and commercializing products for pain management, neurological disorders, cancer, and autoimmune diseases. Their product line includes Nyloxin and Pet Pain-Away, targeting both human and animal pain relief.
Price as of Nov 18, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0002 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0001 – $0.005 | |
| Market capitalisation | $1.43M | |
| Shares traded on the day | 75 |
Price & events
Other perspectives
Council score for Nutra Pharma (NPHC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Nutra Pharma (NPHC), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Nutra Pharma Corp. (NPHC) is the company analyzed here. It employs 6 people and is led by Michael D. Flax. In Q2 FY2026 it reported revenue of $34,463 and net income of -$4M. The market values it at $1.43M.
What do the latest results show for Nutra Pharma (NPHC)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $34,463.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $34,463 | -$4M | -$0.0005 (diluted) |
| Q1 FY2026 | $48,214 | -$459,675 | -$0.0001 (diluted) |
| Q4 FY2025 | $54,066 | -$488,526 | -$0.0001 (diluted) |
| Q3 FY2025 | $70,242 | -$523,520 | -$0.0001 (diluted) |
What are the financial strengths and risks for Nutra Pharma (NPHC)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 30.3% · current ratio 0.02 · free-cash-flow yield -73.3%.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 3
- Purchases
- 5
- Sales
- 0
- Other transactions
- 7
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held NPHC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported NPHC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Nutra Pharma Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the NPHC research dossier (written Mar 15, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What are the main risks for NPHC?
Nutra Pharma Corp. faces several risks, including intense competition from larger pharmaceutical companies, regulatory hurdles in obtaining FDA approvals, and potential product liability claims. The company's limited financial resources and dependence on a small number of products further amplify these risks.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com